Evolve Private Wealth LLC Purchases New Stake in Harmony Biosciences Holdings, Inc. $HRMY

Posted by Brenda Bartman on Jun 26th, 2026

Evolve Private Wealth LLC acquired a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 18,632 shares of the company’s stock, valued at approximately $522,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Amundi grew its position in shares of Harmony Biosciences by 115.6% during the 1st quarter. Amundi now owns 39,668 shares of the company’s stock valued at $1,229,000 after acquiring an additional 21,266 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Harmony Biosciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after purchasing an additional 984 shares during the period. Empowered Funds LLC purchased a new position in Harmony Biosciences in the first quarter valued at approximately $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Harmony Biosciences by 53.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock valued at $3,166,000 after purchasing an additional 33,058 shares during the last quarter. Finally, Cetera Investment Advisers grew its holdings in Harmony Biosciences by 9.8% during the second quarter. Cetera Investment Advisers now owns 8,404 shares of the company’s stock valued at $266,000 after purchasing an additional 748 shares during the period. Institutional investors own 86.23% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on HRMY shares. Zacks Research upgraded Harmony Biosciences from a “strong sell” rating to a “hold” rating in a research note on Friday, May 1st. Weiss Ratings upgraded Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday. Wall Street Zen lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Truist Financial boosted their price objective on Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research note on Friday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Harmony Biosciences in a report on Wednesday. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $40.89.

View Our Latest Report on HRMY

Harmony Biosciences Trading Down 0.9%

Shares of HRMY stock opened at $34.13 on Friday. The company has a market capitalization of $1.98 billion, a PE ratio of 13.76, a price-to-earnings-growth ratio of 0.24 and a beta of 0.96. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.56 and a current ratio of 3.58. The business’s fifty day moving average is $31.83 and its 200 day moving average is $32.95. Harmony Biosciences Holdings, Inc. has a 52-week low of $25.52 and a 52-week high of $40.87.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.21). The business had revenue of $215.39 million during the quarter, compared to analysts’ expectations of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The business’s revenue was up 16.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.78 EPS. On average, equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.2 EPS for the current fiscal year.

About Harmony Biosciences

(Free Report)

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.